J9190 Fluorouracil (HCPCS) Reimbursement & Policy

HCPCS Level II code J9190 denotes a 500 mg unit of fluorouracil (5-FU) injection, a widely used antimetabolite in oncology. Nationally, billing for systemic chemotherapy agents is closely tracked because drug utilization, dosing units, and site-of-service affect cost, patient access, and coverage policies. This code is relevant for hospital outpatient departments, ambulatory infusion centers, and physician office settings where intravenous chemotherapy is administered.

Key payers in this review include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of billing and coding context for J9190, common payer coverage considerations, and clinical context about fluorouracil as a chemotherapeutic agent. The publication also summarizes typical service settings, common modifiers used with HCPCS drug codes, and where data was not available.

The report provides practical benchmarks and policy-relevant points to inform revenue cycle, pharmacy, and oncology clinical operations, including unitization practices, documentation essentials tied to chemotherapy administration, and payer-specific coverage themes. Data not provided in the input are noted explicitly where applicable.

Billing Code Overview

HCPCS Level II code J9190 represents injection, fluorouracil, 500 mg. This code denotes a chemotherapy drug administration for the antimetabolite agent fluorouracil (5-FU) in a 500 mg dosage unit.

Service type: Drug administration (intravenous or per oncologist discretion depending on clinical protocol)
Typical site of service: Hospital outpatient department, ambulatory infusion center, physician office, or oncology clinic

Data not available in the input.

Clinical Context

A typical patient is an adult with a confirmed diagnosis of a solid tumor (for example, colorectal cancer) or a dermatologic malignancy for which systemic or intralesional fluorouracil is indicated. The patient presents to an outpatient oncology infusion center or hospital outpatient department for administration of chemotherapy. The workflow includes verification of the chemotherapy order (drug, dose per body surface area or fixed-dose), pre-infusion nursing assessment (vital signs, allergy check, intravenous access assessment), and review of laboratory results (complete blood count, hepatic and renal panels). Pharmacy compounds J9190 (injection, fluorouracil, 500 mg) in an appropriate sterile environment, labels the syringe or bag with concentration and dose, and confirms dose with the ordering provider. During administration the infusion nurse monitors infusion site, patient tolerance, and documents start/stop times and any reactions. Post-infusion instructions and antiemetic or supportive care orders are reviewed prior to discharge. Typical site of service is an outpatient infusion center or hospital outpatient department; in some cases intralesional use may occur in a procedure room or dermatology clinic with appropriate documentation and monitoring.

Coding Specifications

Modifier	Description	When to Use
`JW`	Drug discarded/not administered	Use when some portion of a single-use vial is discarded and payer requires reporting of wasted drug.

Taxonomy Code	Specialty	Notes
`207Q00000X`	Medical Oncology	Most common specialty administering systemic fluorouracil infusions in outpatient infusion centers.
`207RP1001X`	Hematology/Oncology	Physicians who provide chemotherapy management and dosing.
`207M00000X`	Dermatology	For intralesional or topical fluorouracil applications and procedural management of cutaneous malignancies.
`363L00000X`	Infusion Nurse	Registered nurses specialized in chemotherapy administration and monitoring.
`332B00000X`	Oncology Pharmacy	Pharmacists responsible for preparation and compounding of IV fluorouracil.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`C18.9`	Malignant neoplasm of colon, unspecified	Fluorouracil is commonly used in adjuvant and palliative regimens for colorectal cancer.
`C50.9`	Malignant neoplasm of breast, unspecified	Fluorouracil can be part of combination regimens for breast cancer treatment.
`C20`	Malignant neoplasm of rectum	Fluorouracil is frequently used in rectal cancer chemoradiation and systemic therapy.
`C43.9`	Malignant melanoma of skin, unspecified	Fluorouracil may be used in select cutaneous malignancy regimens or procedural settings.
`D23.9`	Benign neoplasm of skin, unspecified	Topical or intralesional fluorouracil is sometimes used for premalignant or benign keratotic lesions in dermatology.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96413`	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single agent	Common code for administration of an IV infusion of a single chemotherapeutic agent such as fluorouracil when infusion time is up to one hour.
`96415`	Chemotherapy administration, IV infusion; each additional hour	Used when fluorouracil infusion extends beyond the initial hour and additional hourly units are billed.
`96417`	Chemotherapy administration, IV infusion; each additional hour for concurrent infusion	Used for concurrent infusions when applicable in multi-agent regimens.
`96360`	Intravenous infusion, hydration; initial, 31 minutes to 1 hour	May be reported when significant IV hydration is provided before or after fluorouracil administration.
`36415`	Collection of venous blood by venipuncture	Often performed prior to chemotherapy for laboratory monitoring required for safe fluorouracil dosing.

OpenPayer

Summary & Overview

HCPCS J9190: Injection, Fluorouracil 500 mg